|Bid||52.66 x 1800|
|Ask||52.67 x 900|
|Day's Range||52.61 - 53.36|
|52 Week Range||36.15 - 64.94|
|Beta (5Y Monthly)||0.30|
|PE Ratio (TTM)||55.74|
|Forward Dividend & Yield||1.40 (2.64%)|
|Ex-Dividend Date||Aug 13, 2020|
|1y Target Est||60.63|
Positive vaccine news boosts sentiment as the country continues to report record hospitalizations.
In this video from Motley Fool Live recorded on Nov. 23, Corinne Cardina, chief of Motley Fool's healthcare and cannabis bureau, and Brian Orelli, Fool.com contributor, discuss how AstraZeneca's (NASDAQ: AZN) coronavirus vaccine, AZD1222, works. Corinne Cardina: The company is in partnership with the University of Oxford, and they have a vaccine candidate and they just released interim analysis, their Phase III clinical trials, and it showed that their vaccine candidate has an average efficacy of 70% in protecting against the coronavirus.
AstraZeneca (AZN) Forxiga is approved in Japan for chronic heart failure (HF) in patients who are receiving standard of care.